RBO & Co. LLC Invests $750,000 in Pfizer Inc. $PFE

Key Points

• RBO & Co. LLC has acquired a new stake in Pfizer Inc., buying 29,600 shares valued at approximately $750,000.
• Pfizer's quarterly dividend of $0.43 will be paid on September 2nd, representing an annualized yield of 6.7% with a payout ratio of 91.49%.
• Analysts have set an average price target of $28.12 for Pfizer's stock, with ratings ranging from "Strong Buy" to "Sell".

RBO & Co. LLC acquired a new position in shares of Pfizer Inc. (NYSE:PFE - Free Report) in the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 29,600 shares of the biopharmaceutical company's stock, valued at approximately $750,000.

Several other large investors have also modified their holdings of the stock. Clarity Asset Management Inc. purchased a new stake in shares of Pfizer during the fourth quarter worth $27,000. Gould Capital LLC increased its stake in shares of Pfizer by 97.2% in the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock worth $27,000 after purchasing an additional 493 shares during the period. GKV Capital Management Co. Inc. acquired a new stake in Pfizer during the first quarter worth about $27,000. Bayforest Capital Ltd acquired a new stake in Pfizer during the first quarter worth about $28,000. Finally, North Capital Inc. acquired a new stake in Pfizer during the first quarter worth about $28,000. 68.36% of the stock is owned by institutional investors.

Analysts Set New Price Targets

PFE has been the topic of a number of recent research reports. Jefferies Financial Group lifted their target price on Pfizer from $32.00 to $33.00 and gave the stock a "buy" rating in a research report on Wednesday, May 21st. HSBC decreased their target price on Pfizer from $27.00 to $26.00 and set a "buy" rating on the stock in a research report on Monday, May 19th. Leerink Partners decreased their price objective on Pfizer from $28.00 to $26.00 and set a "market perform" rating on the stock in a report on Wednesday, April 30th. Berenberg Bank decreased their price objective on Pfizer from $28.00 to $25.00 and set a "hold" rating on the stock in a report on Thursday, May 29th. Finally, Citigroup lifted their price objective on Pfizer from $25.00 to $26.00 and gave the company a "neutral" rating in a report on Wednesday, August 6th. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Pfizer has a consensus rating of "Hold" and a consensus price target of $28.12.

Pfizer Trading Down 2.8%

PFE stock traded down $0.73 during trading on Monday, hitting $25.15. The company had a trading volume of 32,304,503 shares, compared to its average volume of 45,249,543. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. The firm has a 50-day moving average price of $24.70 and a 200-day moving average price of $24.39. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $30.43. The stock has a market cap of $142.99 billion, a price-to-earnings ratio of 13.38, a PEG ratio of 0.92 and a beta of 0.52.

Pfizer (NYSE:PFE - Get Free Report) last issued its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, beating the consensus estimate of $0.58 by $0.20. The company had revenue of $14.65 billion during the quarter, compared to analysts' expectations of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The business's revenue for the quarter was up 10.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 2nd. Investors of record on Friday, July 25th will be paid a $0.43 dividend. The ex-dividend date of this dividend is Friday, July 25th. This represents a $1.72 dividend on an annualized basis and a yield of 6.8%. Pfizer's dividend payout ratio is presently 91.49%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.